immuneGlobe
Private Company
Funding information not available
Overview
immuneGlobe is a specialized antibody service provider leveraging advanced immunization and purification technologies to produce highly specific custom antibodies for research. The company's platform enables the generation of polyclonal antibodies that can discriminate between subtle protein variants, such as single amino acid mutations or specific phosphorylation states, a capability traditionally associated with monoclonal antibodies. Operating as a B2B service provider, immuneGlobe caters to academic and industrial research clients who require precise tools for proteomics, signaling pathway analysis, and disease mechanism studies. Its business model is built on providing tailored antibody development services rather than developing its own therapeutic or diagnostic products.
Technology Platform
Proprietary immunization, purification, and depletion schemes to generate highly specific polyclonal rabbit antibodies capable of discriminating point mutations, isoforms, and post-translational modifications with monoclonal-like specificity.
Opportunities
Risk Factors
Competitive Landscape
immuneGlobe competes in the custom antibody services segment against other CROs like GenScript, BioGenes, and Pacific Immunology. Its primary differentiation is a claimed technological edge in achieving extreme specificity with polyclonals. It also indirectly competes with the in-house capabilities of large pharmaceutical companies and academic core facilities, as well as the catalog offerings of giants like Abcam and Cell Signaling Technology, which are moving to offer more phospho-specific and mutant-specific antibodies.